Spinal fusion is one of the most performed surgical interventions in the United States, yet the core mechanics of its most critical step — discectomy — have remained stubbornly manual for decades. A surgeon performing a minimally invasive transforaminal lumbar interbody fusion (MIS TLIF) still relies on hand dexterity, physical endurance, and dozens of repeated instrument passes to clear a collapsed disc space — a process that, even under optimal conditions, achieves less than half of all disc fragment removal.
The consequences of this gap are measurable. Incomplete discectomy correlates with fusion complications, prolonged operating times, higher radiation exposure, and elevated revision rates. Against this backdrop, the spine robotic surgery market — valued at $496 million in 2025 and projected to exceed $1.5 billion by 2034 at a CAGR of 13.2% — has attracted well-capitalized incumbents whose platforms navigate and guide, but still leave the discectomy itself to human hands.
Vista Robotics, a San Jose startup founded in December 2020, is building into that gap. Its SpineNova platform performs autonomous discectomy and endplate preparation — the step no current robotic system automates — targeting 90%-plus disc fragment removal in under three minutes, compared to up to 30 minutes of manual instrument passes achieving sub-50% clearance. The company is pre-FDA clearance and Christie Wang, co-founder and CEO with her founding team bring more than a century of combined medtech experience, bridging engineering depth and direct surgical practice exposure to a company whose product design reflects both. The clinical thesis is specific, the market gap is real. 2026 is the year the platform’s credibility will be tested.
A Platform Built Around the Step Everyone Skipped
The incumbents in spine robotics — Medtronic’s Mazor X Stealth Edition, Globus Medical’s ExcelsiusGPS, and Brainlab’s navigation suite — are supervisory systems. The robot positions and plans; the surgeon executes. That architecture has delivered real clinical value in screw placement accuracy and radiation reduction. But none of it has moved into autonomous procedural execution. Discectomy remains fully manual across every platform on the market.
SpineNova targets the full procedural sequence of a minimally invasive lumbar interbody fusion: autonomous discectomy and endplate preparation in a single pass under three minutes, trajectory guidance for interbody cage insertion, and integrated navigation for pedicle screw placement. The clinical stakes are direct — residual disc material compromises the bone-to-cage contact surface that fusion depends on, and disc space preparation quality is a known predictor of outcomes. Vista projects the platform reduces total operative time by 20 to 30 minutes per procedure, compresses time under anesthesia, and removes a source of variability that surgical technique alone cannot reliably control.
“Their platform is AI-guided instead of just mechanically assisted, adaptive through real-world procedural data, and designed to integrate seamlessly into existing surgical workflows.” — TiE Women’s Program Silicon Valley, awards citation, 2025
The roadmap extends beyond lumbar fusion to laminectomy and automated cage insertion — a platform-first design that mirrors how incumbents are thinking. Stryker showcased Mako 4 at the 2025 AAOS Annual Meeting, expanding across hip, knee, and spine — with Mako Spine in limited market release at the time of the event. Globus Medical absorbed NuVasive’s Pulse navigation platform through a $3.1 billion merger. The market is consolidating around integrated surgical ecosystems. SpineNova enters that architecture from a differentiated starting point: not adding spine to an orthopedic robot, but automating the procedural layer those robots leave untouched.
Navigation Incumbents, Procedural Challenger
The competitive reality is unambiguous. Medtronic, Globus Medical, Brainlab, and Zimmer Biomet — alongside Stryker, which divested its U.S. spinal implants business in April 2025 and licensed Mako Spine and Copilot exclusively to the buyer, while retaining its Interventional Spine and Neurotechnology businesses — collectively held approximately 79% of the spine robotics market entering 2025. These companies have installed base, surgeon training infrastructure, and reimbursement pathways that Vista does not.
Vista’s differentiation is structural, not incremental. The company is not competing on navigation accuracy within a well-defined category — it is advancing a claim that the category itself is incomplete. Current-generation platforms address the guidance layer of spinal fusion comprehensively; none have moved into autonomous procedural execution at the discectomy stage. For institutions evaluating robotic investment, SpineNova is positioned not as a navigation upgrade but as an operative efficiency tool that removes the physical burden of repeated manual instrument passes and the variability those passes introduce.
The broader context is structurally favorable. The global surgical robots market is projected to reach $27.1 billion by 2030, driven by MIS adoption, aging demographics, and hospital systems treating robotic capability as an institutional differentiator. Surgeon fatigue and procedural variability remain documented challenges in high-volume spine centers, and the quality of disc space preparation is a known predictor of fusion outcomes in peer-reviewed literature. A platform that reliably closes that variability gap has a defined value proposition in a market that rewards measurable clinical improvement.
Vista’s 2026 execution centers on two parallel tracks: advancing toward an FDA 510(k) or De Novo submission and generating cadaveric or bench validation data sufficient to anchor a Series A. The regulatory pathway for a system that performs autonomous procedural steps is more demanding than for navigation platforms — broader safety evidence, longer timelines, higher capital requirements. That is a harder road. It also produces a more defensible asset if cleared.
Navigation Was Phase One. Autonomy Is the Question Now.
The surgical robotics industry has spent a decade proving that robots belong in the operating room. What the next decade will determine is how deeply they can operate within it. The distinction between a robot that guides a surgeon’s hands and one that autonomously completes a surgical step is not merely technical — it is categorical, and it carries implications for liability frameworks, surgeon training models, hospital credentialing, and the structure of the medtech value chain itself.
Vista Robotics is an early and undercapitalized entrant in a space dominated by some of the most entrenched companies in medical devices. But its core thesis — that the quality of spinal fusion outcomes depends on a procedural step that no current robotic platform has automated — identifies a genuine clinical gap. Whether SpineNova can translate that thesis into cleared, deployable technology within a competitive window remains the open question. The answer will arrive not in a press release but in regulatory submissions, clinical data packages, and eventually, in operating rooms.
The sector is watching. And the geometry of the next-generation spine OR — how much of it is guided, how much is assisted, and how much is autonomous — is still being drawn.